Epigenetic adjuvants : durable reprogramming of the innate immune system with adjuvants
Copyright © 2022 Elsevier Ltd. All rights reserved..
Development of effective vaccines is a critical global health priority. Stimulating antigen-specific B and T cells to elicit long-lasting protection remains the central paradigm of vaccinology. Adjuvants are components that enhance vaccine immunogenicity by targeting specific innate immune receptors and pathways. Recent data highlight the capacity of adjuvants to induce durable epigenetic reprogramming of the innate immune system to engender heightened resistance against pathogens. This raises the prospect of developing epigenetic adjuvants that, in addition to stimulating robust T and B cell responses, convey broad protection against diverse pathogens by training the innate immune system. In this review, we discuss our emerging understanding of the various vaccines and adjuvants and their effects on durable reprogramming of the innate immune response, their putative mechanisms of action, and the promise and challenges of developing epigenetic adjuvants as a universal vaccine strategy.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:77 |
|---|---|
| Enthalten in: |
Current opinion in immunology - 77(2022) vom: 01. Aug., Seite 102189 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Lee, Audrey [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Adjuvants, Immunologic |
|---|
| Anmerkungen: |
Date Completed 02.08.2022 Date Revised 02.08.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.coi.2022.102189 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM341114324 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM341114324 | ||
| 003 | DE-627 | ||
| 005 | 20231226011031.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.coi.2022.102189 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1137.xml |
| 035 | |a (DE-627)NLM341114324 | ||
| 035 | |a (NLM)35588691 | ||
| 035 | |a (PII)S0952-7915(22)00036-X | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Lee, Audrey |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Epigenetic adjuvants |b durable reprogramming of the innate immune system with adjuvants |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 02.08.2022 | ||
| 500 | |a Date Revised 02.08.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2022 Elsevier Ltd. All rights reserved. | ||
| 520 | |a Development of effective vaccines is a critical global health priority. Stimulating antigen-specific B and T cells to elicit long-lasting protection remains the central paradigm of vaccinology. Adjuvants are components that enhance vaccine immunogenicity by targeting specific innate immune receptors and pathways. Recent data highlight the capacity of adjuvants to induce durable epigenetic reprogramming of the innate immune system to engender heightened resistance against pathogens. This raises the prospect of developing epigenetic adjuvants that, in addition to stimulating robust T and B cell responses, convey broad protection against diverse pathogens by training the innate immune system. In this review, we discuss our emerging understanding of the various vaccines and adjuvants and their effects on durable reprogramming of the innate immune response, their putative mechanisms of action, and the promise and challenges of developing epigenetic adjuvants as a universal vaccine strategy | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a Adjuvants, Immunologic |2 NLM | |
| 650 | 7 | |a Vaccines |2 NLM | |
| 700 | 1 | |a Wimmers, Florian |e verfasserin |4 aut | |
| 700 | 1 | |a Pulendran, Bali |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Current opinion in immunology |d 1989-1990 |g 77(2022) vom: 01. Aug., Seite 102189 |w (DE-627)NLM01261923X |x 1879-0372 |7 nnns |
| 773 | 1 | 8 | |g volume:77 |g year:2022 |g day:01 |g month:08 |g pages:102189 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.coi.2022.102189 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 77 |j 2022 |b 01 |c 08 |h 102189 | ||